Navigation Links
HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference
Date:5/6/2011

FRAMINGHAM, Mass., and SYDNEY, May 6, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to make an investor presentation at the Bank of America Merrill Lynch Health Care Conference at 10:40 a.m. Pacific Time (1:40 p.m. ET) on Tuesday, May 10, 2011.  The conference is being held May 10-12, 2011 at the Encore at Wynn in Las Vegas.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  An archived replay of the presentation will also be available shortly after the presentation time until May 27, 2011.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant under a continued access protocol and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
2. HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
3. HeartWare Announces Presentations at The International Society of Heart and Lung Transplantation Annual Meeting
4. HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
5. HeartWare to Present at the Barclays Capital 2011 Global Healthcare Conference
6. HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009
7. HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
8. HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference
9. HeartWare Files PMA Application for FDA Approval of the HeartWare® Ventricular Assist System for a Bridge-to-Transplant Indication
10. HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
11. HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... PHILADELPHIA , March 30, 2017  Lannett Company, ... the company voluntarily made a $25 million payment against ... $25 million payment, combined with the $75 million payment ... us approximately $5.5 million in annualized cash interest expense, ... executive officer of Lannett.  "Our business is solid and ...
(Date:3/30/2017)... Research and Markets has announced the ... & Forecast, By Type (Hemodialysis, Peritoneal Dialysis), By Product (Device, ... 2014 To 2025" report to their offering. ... The global ... 108.5 billion by 2025. Home-based dialysis ...
(Date:3/29/2017)... 29, 2017  Bodycad announced today that it ... 510(k) clearance for its Bodycad Unicompartmental Knee System, ... orthopaedic restoration. Bodycad is the first Canadian company ... implant system. Bodycad,s revolutionary Unicompartmental ... of the patient,s unique anatomical features and kinematics. ...
Breaking Medicine Technology:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, ... each year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, ... efforts focus on finding more effective treatment options, the San Diego Gamma Knife ...
(Date:3/29/2017)... ... ... the main cause of hay fever in the United States, with an estimated 95 percent ... to July each year; with the worst time for sufferers being June and July. ... ) provide an effective defense against grass pollen; they are proven in independent studies to ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are ... it has been used for thousands of years. , "The West has caught on, ... " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of the ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, ... Stores in two southeastern states. Ingredients in HeartBoost, an over the counter heart ...
Breaking Medicine News(10 mins):